Concurrent inhibition of EGFR and JAK2/STAT3 was highly effective in a panel of molecularly heterogeneous glioma stem cells (GSC) and in orthotopic EGFRvIII GSC xenografts [37]. The gene discussed is EGFR; the disease is central nervous system cancer.